Introduction
============

Diabetes mellitus (DM) is considered one of the most epidemic diseases of the 21st century, showing a high prevalence of 2%--6% worldwide.[@b1-opth-12-419] It is a multifactorial metabolic disease clinically presenting as sustained hyperglycemia together with disturbances of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action, or both.[@b2-opth-12-419] Insufficient insulin action arises either due to the damage of β pancreatic cells (type 1) or because the produced insulin does not function sufficiently, which is known as insulin resistance (type 2) DM. The World Health Organization[@b3-opth-12-419] defined DM as a fasting venous plasma glucose level that is equal to or higher than 7.0 mmol/L or venous plasma level is equal to or greater than 11.1 mmol/L, measured 2 hours after oral intake of 75 g glucose.[@b4-opth-12-419]

Diabetic patients are at high risk of developing nephropathy, neuropathy, retinopathy, and cardiac diseases as the four major complications. Diabetic retinopathy (DR) is the most common complication of this chronic disease (approximately 90%).[@b5-opth-12-419] In most of the developing countries, DR is one of the most common contributing factors of blindness.[@b6-opth-12-419] DR clinically presents as retinal ischemia, intraretinal microvascular abnormalities, hemorrhages, neovascularization, and increased vascular permeability.[@b7-opth-12-419] It can progress from mild, nonproliferative to moderate or severe nonproliferative disease, which may consequently result in proliferative disease.[@b8-opth-12-419] This progression of retinopathy might be affected by environmental risk factors such as age, stress, diet, genetic susceptibility, lifestyle, and gut microbiota; the latter is an emerging risk factor that has been recently related to type 2 DM and its complications.

In 2015, the American Diabetes Association reported that according to the Clinical Practice, glycosylated hemoglobin (HbA1c) was recommended as an excellent predictive marker for the diagnosis of diabetes.[@b9-opth-12-419] Each 1% reduction in HbA1c minimizes the risk of developing systemic and ocular complications by 40%.[@b3-opth-12-419] The measurement of HbA1c is considered as important as blood glucose measurement, and it can facilitate the accomplishment of improved glycemic control. HbA1c is a reflection of average plasma glucose over the past 2--3 months and does not require patients to fast and can be measured at any time. Recently, there has been an increased interest to use HbA1c as a marker for screening of those at high risk of developing diabetes as it shows high sensitivity and specificity.[@b10-opth-12-419]

The use of HbA1c is considered as one of the most discriminative and effective tools for the diagnosis of diabetic patients who are vulnerable to develop complications including retinopathy.[@b11-opth-12-419] An association between HbA1c and mortality risk factors among men and women with type 2 diabetes was recently reported.[@b12-opth-12-419] Higher frequency of Gram-positive bacteria such as *Staphylococci* was detected in diabetic patients, especially those with retinopathy.[@b13-opth-12-419]

Current research demonstrated that beneficial bacteria, known as probiotic, can provide a positive impact on HbA1c as a marker of diabetic severity. However, further investigations are recommended for future therapeutic trials of T2DM. This information motivates the interest to test the effectiveness of HbA1c as a predictive biomarker for early development of retinopathy. This will be through an attempt to find correlation between controlled HbA1c (\<7%) and uncontrolled HbA1c (≥7%) on peripapillary retinal nerve fiber layer thickness (RNFLT) in diabetic patients as marker of severity of retinopathy. The obtained data might support the suggestion of the use of the noninvasive probiotic as a protective strategy against retinopathy, a complication of DM that may consequently lead to blindness.[@b14-opth-12-419]

Participants and methods
========================

The study involved 126 eyes of healthy subjects (n=32) and type II diabetic patients (n=31; [Table 1](#t1-opth-12-419){ref-type="table"}; [Figure 1](#f1-opth-12-419){ref-type="fig"}). The study was conducted over the period from the first of January 2016 until the end of April 2016 at the Department of Ophthalmology at the Specialized Medical Center Hospital in Riyadh. Patients with cataract, glaucoma, optic disc anomalies, or any systemic diseases with ocular complications were excluded. Patients were divided into a control group with healthy subjects and two study groups, one (subgroup 1) with HbA1c that is less than 7% and the other (subgroup 2) with HbA1c that is equal or more than 7%. All participants underwent full ophthalmic examination including measurement of refractive error using Auto Refractometer, visual acuity assessment by Snellen chart, slit-lamp anterior segment examination, intraocular pressure measurement using applanation tonometer, fundus examination using +90 dioptre lens, and peripapillary RNFLT measurement using 3D-OCT 2000 (360-degree circular scan with 3.4 mm diameter centered on optic disc).[@b15-opth-12-419] In addition, an assessment of glycemic control was performed using A1cNow^+^ system, which provides quantitative measurement of HbA1c level in a capillary or venous blood sample.[@b16-opth-12-419]

Statistical analysis
--------------------

Statistical analysis was performed using the commercially available statistical software package (SPSS for windows, version 21.0, IBM Corp., Armonk, NY, USA). Both eyes were taken for analysis. Student's *t*-test was used for normally distributed variables. Pearson's correlation analysis was applied according to the distribution type of the variables to analyze the relationship between variables. Analysis of variance has been used to find the significance of the study parameters between three or more groups of data. *p*-value of \<0.05 was considered as statistically significant.

Ethical consideration
---------------------

The protocol of the study was explained to each participant at the time of recruitment and informed written consent was obtained according to the Declaration of Helsinki. The research was approved by the research ethical committee at The College of Applied Medical Sciences, King Saud University.

Results and discussion
======================

DM as a chronic disease can result in multiple complications, one among which is retinopathy. Controlling such a disease is of critical importance in order to avoid the development of different complications. The present study revealed the correlation between the level of HbA1c and RNFLT. Current results showed that the peripapillary RNFLT was affected in the superior quadrant of diabetic patients in relation to glycemic control as compared to healthy subjects ([Table 2](#t2-opth-12-419){ref-type="table"}, [Figures 2](#f2-opth-12-419){ref-type="fig"} and [3](#f3-opth-12-419){ref-type="fig"}). This is consistent with the outcome of previous studies, which demonstrated that RNFLT was decreased in patients with preclinical DR in all 4 quadrants, but the difference was significant only at the superior quadrant.[@b17-opth-12-419],[@b18-opth-12-419] However, the current results are contradictory to those of Chen et al,[@b19-opth-12-419] who reported significant changes in other quadrants as well. This can be attributed to the use of different optical coherence tomography instruments. In addition, this study was conducted for less than 2 months, which might have a negative impact on the sample size, and thus the outcome. The observed variation in the current study may be due to dense arrangement of peripapillary retinal nerve fibers.[@b20-opth-12-419] Also, the present data demonstrate significant thinning in retinal nerve fiber layer in patients with HbA1c \<7% (controlled DM). This reduction was increased in patients with HbA1c ≥7% (uncontrolled DM), in accordance with previous studies ([Table 3](#t3-opth-12-419){ref-type="table"}).[@b18-opth-12-419],[@b21-opth-12-419]

The results of the present study revealed that the reduction in RNFLT was affected in the superior quadrant by the duration of diabetes, presence of DR, and the treatment regimen in insulin users. RNFLT reduced more in oral hypoglycemic users ([Tables 4](#t4-opth-12-419){ref-type="table"}[](#t5-opth-12-419){ref-type="table"}--[6](#t6-opth-12-419){ref-type="table"}), which is consistent with previous studies.[@b18-opth-12-419],[@b22-opth-12-419] Hammes et al[@b18-opth-12-419] described that diabetes can induce apoptosis in retinal ganglion cells and Müller cells in an experimental diabetes model, and this supports the present findings of that RNFLT was decreased prior to the development of DR.

[Table 7](#t7-opth-12-419){ref-type="table"} and [Figure 4](#f4-opth-12-419){ref-type="fig"} demonstrate that the peripapillary RNFLT was negatively correlated with HbA1c in the superior, inferior, and nasal quadrants, while it was positively correlated in the temporal quadrant. This correlation was significant in the superior quadrant only, which is consistent with the findings by Srivastav et al.[@b22-opth-12-419]

Conclusion
==========

Impairment of glycemic control affects the peripapillary RNFLT mainly in the superior quadrant. This thickness also tends to be decrease with long-standing DM, use of DM medications, and development of DR. According to the results of the present study, peripapillary RNFLT may be used as a predictive marker of retinopathy development, which might help to avoid future devastating complications.
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![The affected RNFLT in (**A**) superior quadrant, (**B**) inferior quadrant, (**C**) temporal quadrant, and (**D**) nasal quadrant of the right eye in the studied groups relative to glycemic control.\
**Abbreviations:** DM, diabetes mellitus; I, inferior; OD, right eye; N, nasal; RNFL, retinal nerve fiber layer; RNFLT, RNFL thickness; S, superior; T, temporal.](opth-12-419Fig2){#f2-opth-12-419}

![The affected RNFLT in (**A**) superior quadrant, (**B**) inferior quadrant, (**C**) temporal quadrant, and (**D**) nasal quadrant of the left eye in the studied groups relative to glycemic control.\
**Abbreviations:** DM, diabetes mellitus; I, inferior; OS, left eye; N, nasal; RNFL, retinal nerve fiber layer; RNFLT, RNFL thickness; S, superior; T, temporal.](opth-12-419Fig3){#f3-opth-12-419}

![Pearson's correlation between (**A**) OD superior quadrant and HbA1c, (**B**) OD inferior quadrant and HbA1c, (**C**) OD temporal quadrant and HbA1c, (**D**) OD nasal quadrant and HbA1c, (**E**) OS superior quadrant and HbA1c, (**F**) OS inferior quadrant and HbA1c, (**G**) OS temporal quadrant and HbA1c, and (**H**) OS nasal quadrant and HbA1c.\
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###### 

Age and gender distribution among groups

  -----------------------------------------------------------------------------------
  Age\      Group I\            Group II\    Total        Gender        
  (years)   (healthy control)   (DM)                                    
  --------- ------------------- ------------ ------------ ------------- -------------
  40--49    14 (43.7%)          13 (41.9%)   27 (42.9%)                 

  50--59    14 (43.7%)          13 (41.9%)   27 (42.9%)                 

  60--69    4 (12.5%)           4 (12.5%)    8 (12.7%)                  

  70        0                   1 (3.2%)     1 (1.6%)                   

  Total     32 (50.8%)          31 (49.2%)   63 (100%)    17 (26.98%)   46 (73.02%)
  -----------------------------------------------------------------------------------

**Abbreviation:** DM, diabetes mellitus.

###### 

Mean ± SD of the measured RNFLT in 4 quadrants of both eyes (OD and OS) in diabetic patients compared to healthy controls

  Parameters (mean)   Group I, healthy controls (n=32)   Group II, diabetic patients (n=31)   *p*-value
  ------------------- ---------------------------------- ------------------------------------ -----------------------------------------------------
  OD RNFLT                                                                                    
   Superior (µm)      130.44±12.72                       120.65±11.38                         0.002[\*\*](#tfn3-opth-12-419){ref-type="table-fn"}
   Inferior (µm)      130.47±12.42                       128.42±16.59                         0.580
   Temporal (µm)      76.72±9.69                         77.06±12.00                          0.900
   Nasal (µm)         90.13±16.42                        86.77±19.50                          0.340
  OS RNFLT                                                                                    
   Superior (µm)      131.13±14.59                       120.87±10.40                         0.002[\*](#tfn2-opth-12-419){ref-type="table-fn"}
   Inferior (µm)      127.91±14.23                       128.06±16.51                         0.968
   Temporal (µm)      72.13±10.40                        73.52±10.15                          0.593
   Nasal (µm)         86.84±14.06                        83.06±16.36                          0.329

**Notes:**

Statistically significant value at *p*\<0.05.

Statistically significant value at *p*\<0.01.

**Abbreviations:** OD, right eye; OS, left eye; RNFLT, retinal nerve fiber layer thickness.

###### 

Comparison between peripapillary RNFLT and glycemic control (HbA1c) in all 4 quadrants

  -------------------------------------------------------------------------------------------------------------
  Parameters       Control + subgroup 1\   Subgroup 2\    *p*-value
                   (n=47 \[32+15\])\       (n=16)\        
                   HbA1c \<7%              A1c ≥7%        
  ---------------- ----------------------- -------------- -----------------------------------------------------
  OD RNFLT                                                

   Superior (µm)   129.17±11.51            115.19±11.51   0.000[\*\*](#tfn6-opth-12-419){ref-type="table-fn"}

   Inferior (µm)   131.66±12.79            123.00±17.67   0.039[\*](#tfn7-opth-12-419){ref-type="table-fn"}

   Temporal (µm)   77.30±11.17             75.69±9.89     0.611

   Nasal (µm)      89.74±14.47             84.75±11.29    0.216

  OS RNFLT                                                

   Superior (µm)   129.13±13.04            117.13±11.40   0.002[\*\*](#tfn6-opth-12-419){ref-type="table-fn"}

   Inferior (µm)   129.96±14.10            122.19±17.50   0.079

   Temporal (µm)   73.83±10.07             69.19±10.39    0.177

   Nasal (µm)      85.43±14.94             83.69±16.49    0.697
  -------------------------------------------------------------------------------------------------------------

**Notes:** Data presented as mean ± standard deviation.

Statistically significant value at *p*\<0.01.

Statistically significant value at *p*\<0.05.

**Abbreviations:** HbA1c, glycosylated hemoglobin; OD, right eye; OS, left eye; RNFLT, retinal nerve fiber layer thickness.

###### 

Comparison between peripapillary RNFLT and DM duration (years)

  -----------------------------------------------------------------------------------------------------
  Parameters       Group II\      Group II\      *p*-value
                   DM \<10y\      DM \>10\       
                   (n=16)         (n=15)         
  ---------------- -------------- -------------- ------------------------------------------------------
  OD RNFLT                                       

   Superior (µm)   124.38±6.65    116.67±14.05   0.058

   Inferior (µm)   132.13±13.83   124.47±18.78   0.204

   Temporal (µm)   77.50±13.87    76.60±10.11    0.839

   Nasal (µm)      90.38±10.77    82.93±9.02     0.047[\*](#tfn10-opth-12-419){ref-type="table-fn"}

  OS RNFLT                                       

   Superior (µm)   125.75±4.71    115.67±12.32   0.008[\*\*](#tfn11-opth-12-419){ref-type="table-fn"}

   Inferior (µm)   132.63±13.78   123.20±18.21   0.114

   Temporal (µm)   76.19±10.32    70.67±9.48     0.133

   Nasal (µm)      83.63±17.61    82.47±15.52    0.848
  -----------------------------------------------------------------------------------------------------

**Notes:** Data presented as mean ± standard deviation.

Statistically significant value at *p*\<0.05.

Statistically significant value at *p*\<0.01.

**Abbreviations:** DM, diabetes mellitus; OD, right eye; OS, left eye; RNFLT, retinal nerve fiber layer thickness.

###### 

Comparison between peripapillary RNFLT in 4 quadrants and treatment regimen (oral hypoglycemic and insulin)

  -----------------------------------------------------------------------------------------------------------
  Parameters       Oral hypoglycemic\   Insulin\       *p*-value
                   (n=23)               (n=8)          
  ---------------- -------------------- -------------- ------------------------------------------------------
  OD RNFLT                                             

   Superior (µm)   124.83±8.32          108.63±10.74   0.000[\*\*](#tfn15-opth-12-419){ref-type="table-fn"}

   Inferior (µm)   131.26±13.13         120.25±23.13   0.107

   Temporal (µm)   77.46±12.41          74.50±11.08    0.492

   Nasal (µm)      87.78±10.54          83.88±10.50    0.374

  OS RNFLT                                             

   Superior (µm)   123.91±7.97          122.13±12.10   0.030[\*](#tfn14-opth-12-419){ref-type="table-fn"}

   Inferior (µm)   131.35±14.44         118.63±19.39   0.060

   Temporal (µm)   74.09±9.64           71.88±12.05    0.604

   Nasal (µm)      83.30±16.86          82.38±15.92    0.893
  -----------------------------------------------------------------------------------------------------------

**Notes:** Data presented as mean ± standard deviation.

Statistically significant value at *p*\<0.01.

Statistically significant value at *p*\<0.05.

**Abbreviations:** OD, right eye; OS, left eye; RNFLT, retinal nerve fiber layer thickness.

###### 

Comparison between peripapillary RNFLT in 4 quadrants with DR and NPDR

  ---------------------------------------------------------------------------------------------------
  Parameters       No DR\         NPDR\          *p*-value
                   (n=18)         (n=13)         
  ---------------- -------------- -------------- ----------------------------------------------------
  OD RNFLT                                       

   Superior (µm)   123.11±8.24    117.23±14.35   0.159

   Inferior (µm)   129.50±16.99   126.92±16.59   0.677

   Temporal (µm)   78.72±13.71    74.77±9.17     0.375

   Nasal (µm)      87.56±10.66    85.69±10.60    0.634

  OS RNFLT                                       

   Superior (µm)   124.39±6.50    116.00±12.89   0.046[\*](#tfn18-opth-12-419){ref-type="table-fn"}

   Inferior (µm)   129.00±15.01   126.77±18.96   0.717

   Temporal (µm)   75.44±9.69     70.85±10.55    0.219

   Nasal (µm)      85.17±18.75    80.15±12.48    0.409
  ---------------------------------------------------------------------------------------------------

**Notes:** Data presented as mean ± standard deviation.

Statistically significant value at *p*\<0.05.

**Abbreviations:** DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; OD, right eye; OS, left eye; RNFLT, retinal nerve fiber layer thickness.

###### 

Correlation between glycemic control (HbA1c) and peripapillary RNFLT in 4 quadrants

  Parameters (mean)   *r* (Pearson's correlation)   *p*-value
  ------------------- ----------------------------- ------------------------------------------------------
  OD RNFLT                                          
   Superior (µm)      −0.490                        0.000[\*\*](#tfn20-opth-12-419){ref-type="table-fn"}
   Inferior (µm)      −0.189                        0.138
   Temporal (µm)      0.076                         0.555
   Nasal (µm)         −0.129                        0.314
  OS RNFLT                                          
   Superior (µm)      −0.392                        0.002[\*\*](#tfn20-opth-12-419){ref-type="table-fn"}
   Inferior (µm)      −0.060                        0.640
   Temporal (µm)      0.025                         0.844
   Nasal (µm)         −0.068                        0.597

**Note:**

Statistically significant value at *p*\<0.01.

**Abbreviations:** HbA1c, glycosylated hemoglobin; OD, right eye; OS, left eye; RNFLT, retinal nerve fiber layer thickness.
